Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1996 1
1998 1
1999 1
2002 1
2003 1
2009 2
2010 1
2011 1
2013 1
2014 1
2018 1
2019 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019 Jan;143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5. J Allergy Clin Immunol. 2019. PMID: 30194992 Free article. Clinical Trial.
Dupilumab reduced lesional epidermal thickness versus placebo (week 4, P = .001; week 16, P = .0002). ...Dupilumab also significantly suppressed type 2 serum biomarkers, including CCL17, CCL18, periostin, and total and allergen-specific IgEs. CONCLUSION: Dupilumab-m …
Dupilumab reduced lesional epidermal thickness versus placebo (week 4, P = .001; week 16, P = .0002). ...Dupilumab also significantly …
Application of moisturizer to neonates prevents development of atopic dermatitis.
Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, Shigematsu Y, Yoshida K, Niizeki H, Motomura K, Sago H, Takimoto T, Inoue E, Kamemura N, Kido H, Hisatsune J, Sugai M, Murota H, Katayama I, Sasaki T, Amagai M, Morita H, Matsuda A, Matsumoto K, Saito H, Ohya Y. Horimukai K, et al. J Allergy Clin Immunol. 2014 Oct;134(4):824-830.e6. doi: 10.1016/j.jaci.2014.07.060. J Allergy Clin Immunol. 2014. PMID: 25282564 Free article. Clinical Trial.
BACKGROUND: Recent studies have suggested that epidermal barrier dysfunction contributes to the development of atopic dermatitis (AD) and other allergic diseases. ...A secondary outcome, allergic sensitization, was evaluated based on serum levels of allergen-specifi …
BACKGROUND: Recent studies have suggested that epidermal barrier dysfunction contributes to the development of atopic dermatitis (AD) …
House-dust mite hypersensitivity, eczema, and other nonpulmonary manifestations of allergy.
Tupker RA, de Monchy JG, Coenraads PJ. Tupker RA, et al. Allergy. 1998;53(48 Suppl):92-6. doi: 10.1111/j.1398-9995.1998.tb05006.x. Allergy. 1998. PMID: 10096817 Review.
This is related to the lack of knowledge of the mechanism of how HDM allergens enter the body. Theoretically, there are two possible routes: directly through the epidermis, or by inhalation. ...As opposed to atopy patch testing, we describe another method, namely, " …
This is related to the lack of knowledge of the mechanism of how HDM allergens enter the body. Theoretically, there are two possible …
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis.
Jensen JM, Pfeiffer S, Witt M, Bräutigam M, Neumann C, Weichenthal M, Schwarz T, Fölster-Holst R, Proksch E. Jensen JM, et al. J Allergy Clin Immunol. 2009 May;123(5):1124-33. doi: 10.1016/j.jaci.2009.03.032. J Allergy Clin Immunol. 2009. PMID: 19410693 Clinical Trial.
It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environmental allergens. ...Betamethasone was superior in reducing clinical symptoms and epidermal proliferation; however, it led to e …
It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environment …
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis.
Jensen JM, Pfeiffer S, Witt M, Bräutigam M, Neumann C, Weichenthal M, Schwarz T, Fölster-Holst R, Proksch E. Jensen JM, et al. J Allergy Clin Immunol. 2009 Sep;124(3 Suppl 2):R19-28. doi: 10.1016/j.jaci.2009.07.015. J Allergy Clin Immunol. 2009. PMID: 19720208 Clinical Trial.
It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environmental allergens. ...Betamethasone was superior in reducing clinical symptoms and epidermal proliferation; however, it led to e …
It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environment …
Comparison of standard and modified SPT method.
Zawodniak A, Kupczyk M, Górski P, Kuna P. Zawodniak A, et al. Allergy. 2003 Mar;58(3):257-9. doi: 10.1034/j.1398-9995.57.s73.39_4.x. Allergy. 2003. PMID: 12653802 Clinical Trial.
METHODS: Twenty-one subjects [with an average age of 23 years (SD +/- 2.72)] with known sensitivity to examined allergen extracts were tested with histamine, negative control solution and standard allergen extracts (Allergopharma, Reinbeck, Germany). SPT were applie …
METHODS: Twenty-one subjects [with an average age of 23 years (SD +/- 2.72)] with known sensitivity to examined allergen extracts wer …
Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial.
Jensen JM, Weppner M, Dähnhardt-Pfeiffer S, Neumann C, Bräutigam M, Schwarz T, Fölster-Holst R, Proksch E. Jensen JM, et al. Acta Derm Venereol. 2013 Sep 4;93(5):515-9. doi: 10.2340/00015555-1533. Acta Derm Venereol. 2013. PMID: 23571785 Free article. Clinical Trial.
Patients with atopic dermatitis (AD) have an epidermal barrier dysfunction, which allows invasion of allergens to occur. Stratum corneum skin barrier is formed by corneocytes and extracellular lipids extruded from the epidermal lamellar bodies. In a controlle …
Patients with atopic dermatitis (AD) have an epidermal barrier dysfunction, which allows invasion of allergens to occur. Strat …
Evening primrose oil (Epogam) in the treatment of chronic hand dermatitis: disappointing therapeutic results.
Whitaker DK, Cilliers J, de Beer C. Whitaker DK, et al. Dermatology. 1996;193(2):115-20. doi: 10.1159/000246224. Dermatology. 1996. PMID: 8884146 Clinical Trial.
OBJECTIVE: Pharmacological doses of gamma-linolenic acid (GLA) could improve the water permeability barrier of the epidermis in chronic hand dermatitis. Clinical improvement, changes in the lipogram and epidermal lipid composition could define functional improvement …
OBJECTIVE: Pharmacological doses of gamma-linolenic acid (GLA) could improve the water permeability barrier of the epidermis in chron …
Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells.
Stary G, Klein I, Bauer W, Koszik F, Reininger B, Kohlhofer S, Gruber K, Skvara H, Jung T, Stingl G. Stary G, et al. J Immunol. 2011 Jan 1;186(1):103-12. doi: 10.4049/jimmunol.1002485. Epub 2010 Dec 6. J Immunol. 2011. PMID: 21135170 Clinical Trial.
Notably, we observed increased numbers of dermal FOXP3(+)CD25(+) T cells and epidermal Langerhans cells (LCs) that were associated with upregulated mRNA expression of TGF-beta in lesions of GCS-treated Ni-allergic patients. ...
Notably, we observed increased numbers of dermal FOXP3(+)CD25(+) T cells and epidermal Langerhans cells (LCs) that were associated wi …
Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation.
Kaidbey K, Owens M, Liberda M, Smith M. Kaidbey K, et al. Toxicology. 2002 Sep 2;178(2):175-82. doi: 10.1016/s0300-483x(02)00320-7. Toxicology. 2002. PMID: 12160622 Clinical Trial.
Two preliminary studies assessed the potential photosensitizing properties of the drug, and the third study added measurement of sunburn cell counts (SBC) and deoxyribonucleic acid (DNA) pyrimidine dimer (PD) formation. The three studies were: a 6-week standard photocontact al …
Two preliminary studies assessed the potential photosensitizing properties of the drug, and the third study added measurement of sunburn cel …
12 results